STEMI remains a significant cause of in-hospital mortality, and up to 20% of people go on to develop heart failure. The timing and route of delivery were critical to the observed benefit.
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HIGHLIGHTS
STEMI remains a significant cause of in-hospital mortality, and up to 20% of people go on to develop heart failure.
P188 is a nonionic triblock copolymer The timing and route of delivery were critical to the observed benefit.
SUMMARY
Poloxamer 188 (P188) is a nonionic triblock copolymer believed to prevent cellular injury after ischemia and reperfusion. This study compared intracoronary (IC) infusion of P188 immediately after reperfusion with delayed infusion through a peripheral intravenous catheter in a porcine model of ST-segment elevation myocardial infarction (STEMI). STEMI was induced in 55 pigs using 45 min of endovascular coronary artery occlusion. Pigs were then randomized to 4 groups: control, immediate IC P188, delayed peripheral P188, and polyethylene glycol infusion. Heart tissue was collected after 4 h of reperfusion. Assessment of mitochondrial function or infarct size was performed. Mitochondrial yield improved significantly with IC P188 treatment compared with control ani- (12) . Despite these effects, the CORE (Collaborative Organization for RheothRx Evaluation) trial found no clinical benefit of P188 when given to patients receiving thrombolytic therapy for STEMI (13) . Subsequent decades have led to significant changes in ANIMAL MODEL. Yorkshire pigs, 38 to 42 kg, were used for all studies. The anesthesia, surgical preparation, and data monitoring and recording were performed as described in detail previously (14) . Briefly, pigs were anesthetized with ketamine (10 ml of 100 mg/ml) followed by inhaled isoflurane at a dose of 0.8% to 1.2% for the remainder of the study. Animals were intubated with a 7.0-mm endotracheal tube.
Temperature was measured with an esophageal temperature probe and was maintained at 37.5 AE 0.5 C with a warming blanket throughout the study. Hematocrit was measured at 28%. Blood was added to 
I s o l a t i o n o f m i t o c h o n d r i a . After 4 h of reperfusion,
animals were euthanized and the heart was removed.
Tissue was excised from the area of the second obtuse marginal branch distal to the stent (infarct) as well as the area adjacent to the LAD (nonischemic).
Mitochondrial experiments were performed as described previously (16) . Briefly, excised cardiac PEG was chosen as a viscosity control for P188 on the basis of molecular weight and similar composition;
however, the effect of PEG on blood viscosity was not well described. As shown in Figure 2 , the addition of increasing concentrations of PEG and P188 resulted in similar reductions in whole blood viscosity.
Increasing the shear rate reduced the whole blood viscosity independent of P188 and PEG, partially Figure 1 . for control, P188, delayed P188, and PEG, respectively; p < 0.01) ( Figure 4B ). There were no significant differences between the treatment groups when comparing ischemic tissues or nonischemic tissues.
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P188 Reduces Damage From STEMI
Calcium retention, a measure of mitochondrial membrane integrity and mitochondrial function, In the setting of complex II substrates, mitochondria isolated from the infarct territory of P188-treated animals continued to tolerate higher levels of calcium compared with control, delayed P188, and PEG animals (1,481 nmol vs. 848, 843, and 881 nmol, respectively; p < 0.005) ( Figure 5B ). However, mitochondria from infarct tissue from P188-treated animals also retained significantly greater levels of calcium than the nonischemic mitochondria from P188-treated animals (1,481 vs. 1,005 nmol; p ¼ 0.019). There were no significant differences in calcium retention capacity of the mitochondria taken from control, delayed P188, and PEG animals when infarct and nonischemic tissues were compared. *comparing infarct to nonischemic territory from the same treatment group, and #comparing infarct tissue harvested from the P188 group to infarct tissue from all other groups. Abbreviations as in Figure 1 .
FIGURE 4 Respiratory Control Index of Isolated Mitochondria
The respiratory control index is defined as the ratio of state 3 to 4 respiration. Control (n ¼ 8), P188 (n ¼ 10), delayed P188 (n ¼ 6), and PEG (n ¼ 6) groups were compared as indicated. Complex I substrates (A) and complex II substrates (B) were used. Error bars represent SEM.
Statistical significance (p < 0.05) denoted as: *comparing infarct to nonischemic territory from the same treatment group, and #comparing infarct tissue harvested from the P188 group with infarct tissue from all other groups. Abbreviations as in Figure 1 . Figure 6E ). There were no significant differences between the control, delayed P188, and PEG groups. 
DISCUSSION
This study reports a significant reduction in cardiac injury with decreased infarct size and preserved mitochondrial function after STEMI using a first-inclass membrane stabilizing block copolymer called P188. These findings highlight the importance of copolymer delivery route and timing to achieve meaningful myocardial preservation in reperfusion, as we find that immediate and direct IC infusion, but not delayed peripheral delivery, is essential to prevent myocardial injury. These findings may help explain the negative outcomes of the CORE trial, which applied a delayed and peripheral delivery strategy in an era when thrombolysis was widely used.
Previous studies have proposed 2 distinct mechanisms for the effects of P188. The first, altered blood viscosity leading to improved tissue perfusion, is not the primary mechanism, as PEG infusion fails to provide a similar benefit despite similar viscosity effects. The second proposed mechanism involves reduction in reperfusion injury through stabilization of sarcolemmal membranes damaged by the metabolic derangements of ischemia (11, 12) . Although this mechanism was not tested directly in the current study, it may be supported by the improvement in mitochondrial calcium retention capacity observed.
Direct effects of P188 on mitochondria in situ have not been shown in prior studies and are beyond the scope of the current study. Further studies will be required to elucidate the specific mechanism of the benefit. The cumulative calcium infused up to the point of mitochondrial permeability transition pore opening is compared for control (n ¼ 8), P188 (n ¼ 10), delayed P188 (n ¼ 6), and PEG (n ¼ 6) groups as indicated. Substrates specific for complex I (A) and complex II (B) were used. Error bars represent SEM. Statistical significance (p < 0.05) denoted as: *comparing infarct to nonischemic territory from the same treatment group, and #comparing infarct tissue harvested from the P188 group with infarct tissue from all other groups. Abbreviations as in Figure 1 .
Ischemia-reperfusion has previously been shown to reduce mitochondrial respiration predominantly at complex I in agreement with the current findings P188 has also shown a direct benefit in neurons exposed to ischemia with prevention of apoptosis and preservation of the blood-brain barrier (22, 23) .
The CORE trial discovered a significant reduction in the renal function of patients receiving P188. This was particularly prominent in elderly patients and in those with pre-existing renal disease. Subsequent studies have demonstrated a reduction in the renal effects of P188 when the compound is purified to reduce low molecular weight contaminants (24) . The P188 used in our study was highly purified in its commercial form, presumably limiting the renal effects. No difference was observed in creatinine after 4 h of treatment, although renal dysfunction may not materialize until later in the course and must be studied further.
STUDY LIMITATIONS. First, this study does not elucidate a clear mechanism of action for P188.
Further, although the dose was chosen on the basis of that used in prior animal studies and the CORE trial, dose optimization was not undertaken. It is clear from our study that timing and route of delivery have a significant effect on outcomes, possibly due to the higher effective dose when delivered directly into the coronary arteries. Although this suggests that a significantly higher systemic dose may provide a similar benefit if delivered early in reperfusion, potential side effects of treatment may also become more prominent. These studies would not be expected to demonstrate a significant reduction in benefit, as the early predictors of infarct size and cTnI release are wellestablished to correlate with long-term outcomes.
CONCLUSIONS
This study demonstrates a substantial cardiac benefit of P188 after STEMI using a clinically relevant 
